In this study, the Breast AI system is evaluated for its ability to assess treatment response in patients undergoing chemotherapy for breast cancer, with a focus on HER2-targeted therapy using trastuzumab (Herceptin). This evidence concerns the gene ERBB2 and breast carcinoma.